Intellia Therapeutics

Intellia is a clinical-stage biotech developing one-time, in vivo CRISPR/Cas9 gene-editing therapies delivered via lipid nanoparticles (LNP) to the liver. Two lead programs: lonvo-z (lonvoguran ziclumeran, ex-NTLA-2002) — a KLKB1 knockout for hereditary angioedema (HAE); and nex-z (nexiguran ziclumeran, ex-NTLA-2001) — a TTR knockout for transthyretin (ATTR) amyloidosis. No product revenue yet; collaboration revenue only.

Pre-revenue, pre-profit; funded into 2028. No debt of note disclosed in the headline financials.

Unchanged. Intellia is a clinical-stage in-vivo CRISPR/Cas9 company. Lead: lonvo-z (lonvoguran ziclumeran, KLKB1 knockout) for hereditary angioedema — 100% Intellia economics. Second: nex-z (nexiguran ziclumeran, TTR knockout) for ATTR amyloidosis — co-developed with Regeneron.

• monetization model: Pre-commercial; no product sales. Revenue from collaboration/license agreements — upfront fees, R&D funding/cost reimbursement, development & commercial milestones, and future royalties; prospective commercial model is a one-time, single-dose gene-editing therapy billed per patient (10-K FY2024, "Business" and "Collaboration Agreements" notes) — sec.gov ; accession number UNKNOWN.
• revenue mix: One reportable segment. Essentially all revenue is collaboration revenue from Regeneron, Otsuka and Kyverna (Novartis historically). Per-counterparty % share: UNKNOWN (customer-concentration is disclosed in the revenue note, not a segment split). Zero product, consumables, service or SaaS revenue (same 10-K; 10-Q revenue note).
• who pays: Currently pharma/biotech partners — Regeneron, Otsuka, Kyverna — funding R&D and paying milestones. Post-approval, the payer would shift to insurers/providers.
• margin_value_capture: No product gross margin (no COGS). Operating margin deeply negative; burn funded by cash, partnerships and equity. Value accrues to the CRISPR/Cas9 + LNP IP platform and clinical de-risking of nex-z / lonvo-z, not to current unit economics.

• customer classes: Pharma & Biotech (current collaboration counterparties); prospective commercialization: Health Systems & Providers, Payers & Insurers.

Note: accession numbers and any quantitative revenue splits are marked UNKNOWN rather than estimated; verify against the current 10-K/10-Q on EDGAR (CIK 0001652130).

Intellia Therapeutics is a clinical-stage genome editing company. Its commercial model is not product sales; it is collaboration revenue derived from strategic pharma partnerships, milestone payments, cost reimbursement, and future royalties. The company has no marketed products and therefore no product gross margin. This is a binary, development-stage biotech model: the economic asset is the CRISPR/Cas9 platform and a set of clinical/edit candidates; the revenue today is secondary to the pipeline.

This structural fact is from the FY2023 Form 10-K, Item 1, Business: Intellia describes itself as a “genome editing company focused on developing potentially curative therapeutics leveraging CRISPR/Cas9” and discloses that it has not generated any revenue from product sales.

Intellia’s monetization model has two phases:

1. Current phase—collaboration cash inflows. Partners pay Intellia for R&D services, access to platform rights, and achievement of research/development milestones. These payments are recognized as collaboration revenue over the performance period or on achieved milestones. Future commercial milestones and royalties are contingent on successful development and approvals.
2. Future phase—product/cure economics. If NTLA-2001, NTLA-2002, or another candidate is approved, Intellia would transition to product sales—likely U.S. commercial launch first, then ex-U.S. via partners or own infrastructure. The company has not established a commercial sales force, and in the 10-K it discusses commercialization risk, manufacturing scale-up, and reimbursement risk.

Today, Intellia sells R&D collaboration rights and services to sophisticated biopharmaceutical licensees. The buyer is not a patient or a hospital; it is a pharma partner that pays for access to CRISPR technology and shares downstream economics. The named parties in the filing are:

• Regeneron Pharmaceuticals — strategic partner.
• Novartis Institutes for BioMedical Research — strategic partner.

These are the only counterparties named as material collaborators in the cited 10-K.

Collaboration revenue $7.7M in Q2 2026 (vs $14.2M Q2 2025; decline from reduced Regeneron revenue). R&D $82.6M, G&A $37.8M, net loss $106.6M in Q2 2026. Cash + marketable securities $628.4M (6/30/26) after a ~$195M April 2026 equity raise. All figures XBRL us-gaap (CIK 0001652130), 10-Q filed 2026-08-06.

The healthspan thesis at the "Repair" layer is durability of intervention. Intellia is the first company to prove, in a registrational Phase 3 trial, that an in-vivo CRISPR edit can durably knock down a disease-driving protein (KLKB1 → kallikrein/bradykinin) to a degree that renders patients both attack-free AND free of chronic prophylactic therapy. That is the quantitative bottleneck: the modal shift from transient RNAi/protein knockdown to permanent DNA-level knockout.

1. Editing depth → attack suppression (efficacy constraint, from HAELO / EX-99.1): mean monthly attack rate 0.26 (lonvo-z) vs 2.10 (placebo) over weeks 5–28 → 87.6% reduction (p<0.0001); 62% of patients attack-free AND therapy-free vs 11% placebo; all TEAEs Grade 1/2, zero SAEs. The 87% attack-rate cut is the empirical readout that biallelic KLKB1 knockout clears the protein-suppression threshold a chronic drug can only approximate transiently.
2. Runway (financial constraint, XBRL): $628.4M cash + marketable securities ÷ $106.6M Q2 net loss ≈ 5.9 quarters ≈ into 2028 — matches management's "fund operations at least into 2028, well beyond the H1 2027 launch," excluding future lonvo-z revenue. Caveat: burn rises with commercial buildout (G&A +39% YoY already), so the "into 2028" guide assumes the April 2026 raise plus either launch revenue or another raise.
3. Cost-of-moat vs moat-defended (illustrative): chronic HAE prophylactics run roughly $300K–$600K/yr US (consensus-approximate); a one-time gene edit priced in the $2M-range (benchmarked to Zolgensma ~$2.1M / Casgevy ~$2.2M) costs ~3–6× one year of chronic therapy but eliminates a ~$9M–$18M undiscounted 30-year chronic stream. The one-time modality's pricing power is bounded by that chronic-cost denominator — the same math that caps it also defines its capture.

1. Priority-Review clock (time-to-monetize, measured).

• BLA accepted September 8, 2026; PDUFA March 10, 2027 = 183 days (~6.0 months) of Priority Review vs a standard ~10-month clock that would have landed ~July 2027.
• Compression ≈ 4 months pulled forward. The 08-22 note's "H1 2027 launch" is now pinned to a specific action date, and FDA "is not currently planning to hold an advisory committee" (8-K Item 8.01 / EX-99.1 2026-09-08) — a process-risk reduction, not an approval.

2. HAELO efficacy still the editing-depth constraint (measured, restated because the BLA rests on it).

• Phase 3 HAELO: 80 patients, one-time 50 mg lonvo-z, Type 1/2 HAE, ages 16+ (EX-99.1 2026-09-08).
• Mean monthly attacks weeks 5–28: 0.26 vs 2.10 placebo → 87% reduction (p < 0.0001).
• 62% of lonvo-z patients were entirely attack-free AND HAE-therapy-free for the six-month evaluation vs 11% placebo (p < 0.0001).
• All TEAEs Grade 1/2; zero SAEs in the lonvo-z arm as of the Feb 10, 2026 cutoff.
• Prevalence cited by the company: 1 in 50,000 people (EX-99.1 2026-09-08). US headcount TAM is not in the filing — left unknown.

3. Runway + OrbiMed facility (capital-structure calc, 8-K 2026-09-04).

Facility anatomy (Credit Agreement with OrbiMed Royalty & Credit Opportunities IV/V; five-year term, maturity September 4, 2031):

• Interest: greater of 3.00% or 1-month SOFR, plus 6.15% margin (8-K Item 1.01) → minimum 9.15%/yr if the 3% floor binds before the margin (standard reading; live SOFR not in the filing → unknown).
• Security: first-priority lien on substantially all assets, including intellectual property (8-K Item 1.01).
• Covenant: maintain ≥ $50M liquidity in controlled accounts until FDA approves the lonvo-z BLA.
• Cash at 6/30/26: $628.4M cash + marketable securities (EX-99.1 2026-08-06). XBRL recon: cash $106.128M + current marketable $331.631M + noncurrent marketable $190.595M = $628.354M (CIK 0001652130, 10-Q).
• Q2 2026 net loss $106.634M (XBRL NetIncomeLoss frame CY2026Q2). H1 operating cash outflow $200.459M (XBRL).
• Drawn $75M ÷ $106.6M/qtr net loss ≈ 0.70 quarters of extra coverage. Optional FDA-approval $75M ≈ another 0.70 quarters, gated on the March 10, 2027 PDUFA. Committed-style capacity excluding the $100M mutual bucket = $300M ≈ 2.8 quarters of Q2-loss coverage.
• Floor interest on the $75M drawn: $75M × 9.15% ≥ $6.86M/year ≈ 6.4% of annualized Q2 net loss ($106.6M × 4 = $426.4M). That is cheap vs the April 2026 equity raise (~$195M net proceeds, EX-99.1 2026-08-06) that accompanied the share count moving 116.317M (12/31/25) → 140.018M (6/30/26) — a +20.4% share increase in six months, of which the offering is the dominant but not sole driver (SBC also).
• Management still guides existing cash (pre-facility) "at least into 2028" excluding lonvo-z commercial revenue (EX-99.1 2026-08-06). The facility is launch-capex insurance, not a going-concern patch.

4. Cost of the "non-dilutive" label (disconfirming, measured).

• The IP lien is the price of avoiding another 20%-class equity round: if Intellia trips a default (payment, covenant, change of control), OrbiMed is ahead of equity on the CRISPR estate. The $50M pre-approval liquidity covenant also caps how far cash can fall during the PDUFA window.
• G&A already jumped to $37.824M in Q2 2026 vs $27.2M in Q2 2025 (EX-99.1 / XBRL) as commercial infrastructure is built before any product revenue — the launch is being funded in cash, now partly with secured debt.

• technical_scarcity: 8/10 — still the only registrational in-vivo CRISPR dataset (HAELO, 87% attack-rate cut, 62% attack-and-therapy-free). Priority Review + no-AdComm is a qualification-barrier confirmation, not new physics. Not 9: foundational Cas9 IP remains licensed/shared; LNP is partly commoditized; nex-z still carries an undisclosed-prevalence HLA gating.
• economic_capture: 5/10 — unchanged. Zero product revenue; Q2 collaboration revenue $7.7M vs R&D $82.6M (R&D/revenue ≈ 10.8×). 100% economics on HAE, ~75% on ATTR (Regeneron cost/profit share from the 08-22 10-Q read) remain options on a March 2027 approval, not capture. OrbiMed's willingness to lien the IP is revealed-preference that a healthcare credit fund will underwrite the launch — it is not pricing power.
• time_to_monetize: 9/10 (from 8/10) — the catalyst is now a calendar date: PDUFA March 10, 2027, Priority Review, no AdComm currently planned. Optional $75M approval tranche is explicitly gated on that event. Residual: approval ≠ reimbursement, and launch G&A is already running.

Hypothesis verdict: STRENGTHENED. The 08-22 STRENGTHENED call (HAELO crossed the pivotal-evidence gate) is confirmed by the FDA actually filing the BLA with Priority Review and a dated PDUFA. The OrbiMed facility removes a near-term dilution risk into that window but puts a first-priority lien on the CRISPR IP and does not create revenue. Not a further upgrade: capture is still $0 product sales.